Church of PeptidesSearch
Portrait of Tirzepatide
New Disciples · approved 2022 onward

Tirzepatide

The Twin-Key Bearer

United States

Tirzepatide acts at both GIP and GLP-1 receptors, pathways involved in glucose regulation and appetite. Mounjaro and Zepbound contain the same molecule but have separate approved indications and product labels.

Evidence ladder: Approved human useApproved human use · product-specific labelsEducational record
ClassificationNew Disciples
Evidence summaryApproved human use · product-specific labels
OriginUnited States
Scientific record

What the evidence says

Approved human uses

  • Mounjaro is FDA-approved to improve glycemic control in people with type 2 diabetes under its current label.
  • Zepbound is FDA-approved under separate labeling for chronic weight management and obstructive sleep apnea in adults with obesity.
  • Clinical evidence must be matched to the exact product, population, indication, and outcome studied.

Side effects, warnings, and limits

  • Gastrointestinal adverse reactions are common and can be serious.
  • Current labels include a boxed warning about thyroid C-cell tumors observed in rats; relevance to humans is unknown.
  • Contraindications and additional warnings apply under the product-specific labeling.
  • Approved products must be distinguished from unapproved or counterfeit copies.
Doctide’s verdict

Two keys opened important clinical doors. Doctide still checks the name above each door: diabetes, weight management, and obstructive sleep apnea are distinct indications with specific eligibility and evidence, not interchangeable promises.

Documented history

Where the real story begins

Tirzepatide entered U.S. approved use as Mounjaro in 2022. Its development connected a dual-receptor design with clinical programs evaluating diabetes and obesity; Zepbound subsequently received separate labeling for weight management and obstructive sleep apnea in adults with obesity. Historical source.

United States · approved 2022 onward
Book of the Canon · comic scripture

The laboratory legend

Tirzepatide arrived with two keys marked GIP and GLP-1. He opened both doors, then refused to let Doctide call every vial bearing his name the same medicine.

This bold passage is invented comedy, not scientific or historical fact.
Questions readers ask

Plain-language answers

What is tirzepatide used for?

Under current U.S. labels, Mounjaro is used to improve glycemic control in people with type 2 diabetes. Zepbound has separate approved uses for chronic weight management and obstructive sleep apnea in adults with obesity. The exact product and label matter.

Is tirzepatide FDA-approved?

Yes, in specific FDA-approved products with product-specific indications and labels. Approval does not automatically extend to every use or formulation.

What pathways does tirzepatide target?

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

Are Mounjaro and Zepbound interchangeable names?

They contain tirzepatide, but they have separate product labels and approved indications. Read the current official label for each product.

Is tirzepatide the same as Ozempic?

No. Tirzepatide acts at both GIP and GLP-1 receptors, while Ozempic contains semaglutide, a GLP-1 receptor agonist. They are different medicines with separate product labels.

Continue with the GLP-1, GIP and glucagon guide for broader comparisons.

Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 22, 2026
Evidence ledger

Primary sources

  1. FDA prescribing information: Mounjaro (revised January 2026)
  2. FDA prescribing information: Zepbound (revised February 2026)
  3. SURMOUNT-1: randomized trial in adults with obesity, 2022

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.

The Book of Trials

Follow the research journey

Join Subject One for six short chapters, from laboratory and animal studies to human trials and today’s evidence.

Read the Tirzepatide journey →